Latest Breaking News On - Urogen pharma ltd - Page 13 : comparemela.com

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Phase 3 ATLAS Clinical Trial Shows UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 .

Mark schoenbergSandip prasadUrogen rtgelMorristown medical center atlantic health systemUrogen pharma ltdDrug administrationUrogen pharmaChief medical officerGenitourinary surgical oncologyMorristown medicalAtlantic health systemChief investigatorNew drug applicationPrivate securities litigation reform actRisk factorsQuarterly report

Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring

/PRNewswire/ DelveInsight s Bladder Cancer Market Insights report includes a comprehensive understanding of current treatment practices, bladder cancer.

United kingdomUnited statesEmtora biosciencesOcellaris pharmaTakara bioKlus pharmaTransthera biosciencesFidia farmaceuticiUrogen pharmaPrnewswire delveinsightAstellas pharmaShruti thakurBristol myers squibbInnocare pharmaTaizhou hanzhongEli lilly

DelveInsight Business Research, LLP: Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring

DelveInsight Business Research, LLP: Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPrnewswire delveinsightTakara bioUrogen pharmaTransthera biosciencesBristol myers squibbAstellas pharmaShruti thakurInnocare pharmaKlus pharmaOcellaris pharmaFidia farmaceuticiEli lillyTaizhou hanzhongEmtora biosciences

LADENBURG THALM/SH SH Increases UroGen Pharma (NASDAQ:URGN) Price Target to $52 00

LADENBURG THALM/SH SH Increases UroGen Pharma (NASDAQ:URGN) Price Target to $52 00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesUrogen pharmaOpaleye management incStonepine capital managementMillennium managementUrogen pharma ltdWells fargo companyAmerica corpFree reportGen pharmaGet free reportCapital managementGen pharma ltdUrogen pharma daily

UroGen Pharma (URGN) Scheduled to Post Quarterly Earnings on Thursday

UroGen Pharma (URGN) Scheduled to Post Quarterly Earnings on Thursday
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Urogen pharmaUrogen pharma ltdRenaissance technologiesSwiss national bankBarclays plcGet free reportGen pharmaNational bankGen pharma ltdUrogen pharma daily